CRISPR Therapeutics AG
Company Stats
- Market Cap
- $5.3B
- as of Sep 30, 2026
- Shares Outstanding
- 96.7M
- Free Float
- 81.7%
Income Statement
- Revenue
- $3.5M
- Operating Income
- -$664.6M
- Net Income
- -$581.6M
- EBITDA
- -$645.1M
- Revenue Growth, 3Y
- 43.1%
- FCF Margin, 3Y Avg
- -3438.6%
- FCF Margin, Worst Year
- -9855.5%
Cash Flow
- Free Cash Flow
- -$345.9M
- FCF Yield
- -6.5%
- Owner FCF Yield
- -7.8%
Balance Sheet
- Cash & Equivalents
- $347.6M
Returns & Capital
- SBC, 3Y Avg
- $80.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $3.5M | -$345.9M | -9855.5% |
| FY2024 | $37.3M | -$144.7M | -387.7% |
| FY2023 | $371.2M | -$269.8M | -72.7% |
| FY2022 | $1.2M | -$532.9M | -44484.9% |
| FY2021 | $915.0M | $457.3M | 50.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back